News

Funding supports trial of TT-P34 as potential treatment

Teitur Trophics has raised €28 million (about $29.7 million) to advance its lead candidate, TT-P34, into a Phase 1b clinical trial as a possible treatment for Parkinson’s and other neurodegenerative diseases. “There is a pressing need for new therapies for neurodegenerative diseases which have a detrimental impact on…

Plans scrapped for Xadago trial for levodopa-induced dyskinesia

Newron Pharmaceuticals and Zambon Pharma have ended their plans to run a clinical trial to test Xadago (safinamide) for uncontrolled movements induced by levodopa in people with Parkinson’s disease. Xadago is widely approved as an add-on treatment to help manage Parkinson’s off episodes, or periods when symptoms…

Parkinson’s, specific cancers share genetic risk factors: Study

Researchers have found a genetic association between Parkinson’s disease and melanoma, a type of skin cancer, and prostate cancer. Data also showed that Parkinson’s genetic risk factors are linked to an increased risk of breast cancer and lower risk of ovarian cancer. “Our results suggest the importance of shared genetic…

Inbrija, inhaled levodopa for patients’ off episodes, arrives in Spain

Inbrija (levodopa inhalation powder), an approved therapy for off episodes in Parkinson’s patients on certain standard levodopa-based treatments, is now available in Spain. Developed by Acorda Therapeutics, the therapy was approved in the U.S. in 2018 and for the European Union in 2019. In Spain and Germany — where…